Hexagon Capital Partners’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Hexagon Capital Partners’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-133	Closed	-$3.34K	–	722
2025 Q1	$3.34K	Buy	133 +60	+82%	+$1.52K	﹤0.01%	1278
2024 Q4	$2.01K	Buy	73 +68	+1,360%	+$1.9K	﹤0.01%	1414
2024 Q3	$144	Buy	+5	New	+$136	﹤0.01%	1510
2023 Q1	–	Sell	-47	Closed	-$2.09K	–	1469
2022 Q4	$2.09K	Sell	47 -114	-71%	-$4.8K	﹤0.01%	1077
2022 Q3	$7K	Buy	+161	New	+$8.25K	﹤0.01%	850

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hexagon Capital Partners's LKFT Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2025, closing a stake of 133 shares — an estimated $3.34K sold.

Hexagon Capital Partners first reported a position in LKFT in Q3 2022 and held it in 5 quarters. The position peaked at $7K in Q3 2022. 85 funds tracked by Wall St. Rank hold LKFT as of Q2 2025.

Hexagon Capital Partners reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 133 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2025, an estimated $3.34K.
Hexagon Capital Partners first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2022 and held it in 5 quarters.
Hexagon Capital Partners's Lakefront Biotherapeutics American Depositary Shares position peaked at $7K in Q3 2022.
85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.